Drug-induced liver injury (DILI) accounts for >50% acute liver failures, and is the leading cause of drug development failure, boxed warning and market withdrawal of approved drugs. Inhibition of BSEP and MDR3 is one of the underlying mechanisms for DILI. BSEP and MDR3 are the primary hepatic transporters responsible for exporting bile salts and phosphatidylcholine, respectively. In humans, inhibition of BSEP and/or MDR3 can result in serious liver injury. This presentation will discuss our patented platforms BSEPcyte® and MDR3cyte® using primary hepatocytes in suspension for higher throughput assessment of DILI potentials. In addition, a brief review of the critical transporter studies to inform DDI potentials will also be discussed. This presentation will benefit scientists wanting to learn more about DILI and/or those needing guidance on crucial transporter studies for better assessment of DDI potentials that is aligned with regulatory guidance. 

Featured Speakers

Dr. Kan He, PhD

General Manager
Biotranex, a Frontage Laboratories Company

Dr. Kan He is the General Manager of Biotranex, a wholly-owned subsidiary of Frontage Laboratories, Inc. Dr. He has extensive experience in pharmaceutical and biotech industries including as the Presidents of Biotranex (2012-2020), Eternity Biosciences and UniTris Biopharma (2008 to 2012).  He held scientific and managerial positions of increasing responsibility at BMS and DuPont Pharmaceutical Co. (2000 to 2008), and Pfizer (formerly Parke-Davis Pharmaceutical/Warner-Lambert Co, 1997 to 2000). Dr. He made important contributions to the discovery and development of apixaban (Eliquis). He also contributed to the development of dasatinib (Sprycel), saxagliptin (Onglyza), and troglitazone (Rezulin), and the discovery of several experimental medicines in clinical development. Dr. He has more than 60 scientific papers and is the inventor on 14 US and international patents.


Register now for this webinar